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Abstract: Elizabethkingia species (spp.), which can colonize hospital environments, are emerging
nosocomial pathogens presenting high mortality. Due to their intrinsic resistance to a broad range
of antibiotics, optimal antibiotic dosage has yet to be determined against infections caused by
Elizabethkingia spp. This study aimed to investigate the risk factors for the mortality of infections
caused by Elizabethkingia spp. and assess the clinical implications of their antimicrobial susceptibility
patterns. Data from 210 patients affected by Elizabethkingia-induced pneumonia and bacteremia
between 1 November 2005 and 31 May 2016, were analyzed. Further antimicrobial susceptibility
tests for moxifloxacin, rifampin, and vancomycin using Elizabethkingia isolates were performed to
compensate for the Elizabethkingia spp. susceptibility panel in patients affected after 2013. The mean
age of the patients was 66.5 ± 18 years and the 28-day mortality rate was 25.2% (53/210). In the
univariate analysis, history of prior stay in an intensive care unit, central venous catheter use,
presented thrombocytopenia, immunocompetent status, a high simplified acute physiology score
II (SAPS II score), a high C-reactive protein (CRP)/albumin ratio on the day of isolation and seven
days later, and a high minimum inhibitory concentration (MIC) value of rifampin were significantly
associated with a higher mortality rate. In the multivariate logistic regression analysis, the MIC
values of rifampin (odds ratio (OR): 1.045; 95% confidence interval (CI): 1.006–1.085; p = 0.023), SAPS
II score (OR: 1.053; 95% CI: 1.022–1.084; p = 0.001), and initial CRP/albumin ratio (OR: 1.030; 95% CI:
1.009–1.051; p = 0.004) were significantly associated with 28-day mortality. To reduce the mortality
associated with Elizabethkingia infections, prediction of the clinical course using initial CRP/albumin
ratio and SAPS II and early intervention are essential. Rifampin is a promising candidate as the drug
of choice in treating Elizabethkingia infections.
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1. Introduction
Elizabethkingia species (spp.) are non-fermentative, non-motile, oxidase-positive, and non-glucose-
fermenting Gram-negative aerobic bacilli [1,2]. They are ubiquitous saprophytes found in freshwater,
saltwater, and soil environments [3]. They can also survive in chlorine-treated municipal water
supplies. Colonized sink basins and taps are potential reservoirs of Elizabethkingia spp. infection
in hospital settings [4,5]. Elizabethkingia spp. does not constitute human microflora [6]; however,
it may colonize patients via fluid contaminated medical devices (e.g., respirators, intubation tubes,
humidifiers, incubators for newborns, and even antiseptic and saline solutions [4,7–9]. It can spread by
wet and dry materials and surfaces, including the hands of hospital staff [10].
Six species are assigned to Elizabethkingia genus, Elizabethkingia meningoseptica, Elizabethkingia
miricola [1], Elizabethkingia anophelis [11], Elizabethkingia bruuniana, Elizabethkingia ursingii,
and Elizabethkingia occulta [12], with the first three considered to be medically important [13].
They generally possess low virulence, and thus, positive clinical cultures usually represent colonization.
Hsu et al. (2012) reported that among E. meningoseptica isolated subjects, approximately half of adults
and one-third of neonates were colonizers [14].
Two or three decades ago, E. meningoseptica was emerging as a nosocomial pathogen but nowadays,
E. anophelis is more prevalent and likely to cause lethal opportunistic infections [15]. It can be explained
why E. meningoseptica is currently the most well-known species. Elizabethkingia spp. can especially
affect the patients that undergo chronic hemodialysis therapy, trauma victims with multiple injuries,
patients undergoing medical and surgical interventions, and patients showing immunosuppression,
prolonged hospital stay, use of an indwelling central venous catheter and other invasive medical
devices, and exposure to multiple broad-spectrum antibiotics [16–19]. Previous researchers have
established that this species is a dangerous opportunistic bacterial pathogen, causing meningitis,
pneumonia, septic arthritis, osteomyelitis, endocarditis, conjunctivitis, cholangitis, urinary tract
infection, cellulitis, abdominal infections, epididymitis, prolonged hospital bronchitis, sinusitis,
dialysis-associated peritonitis, and prosthesis-associated joint infection in humans [13,14,20–24].
It is known that Elizabethkingia spp. has virulence factors including a propensity for biofilm
formation [2], intracellular invasion [25], and chromosomal- [26] and plasmid-mediated [27] resistance
to many antimicrobial drugs, including commonly used β-lactams [1]. For example, E. meningoseptica
possesses two different types of β-lactamases (intrinsic class A extended-spectrum serine-β-lactamases
and inherent class B metallo-β-lactamases), which makes it resistant to a broad range of antimicrobials
that are routinely used for empiric treatment of infections caused by Gram-negative bacteria [26,
28]. For that reason, E. meningoseptica is generally resistant to carbapenems, extended-spectrum
cephalosporins, aminoglycosides, aztreonam, and colistin [29,30]. It is no wonder that E. meningoseptica
has emerged as a very successful nosocomial pathogen causing severe life-threatening infections in
intensive care units where there is selective antibiotic pressure due to the higher antibiotic use [16].
The mortality associated with E. meningoseptica infection is alarmingly high (33–52%) [18], especially in
patients who have received inappropriate initial antimicrobial therapy [2,31].
So far, however, there is no antimicrobial regimen of choice for empiric treatment of Elizabethkingia
spp. infections, as antimicrobial susceptibilities have been inconsistent across reports [32]. Interestingly,
E. meningoseptica is often susceptible to agents generally used to treat infections caused by Gram-positive
bacteria such as rifampicin, clindamycin, erythromycin, trimethoprim-sulfamethoxazole (TMP-SMX),
quinolones, and vancomycin.
In this study, we analyzed subjects showing Elizabethkingia spp. infections clinically and
microbiologically. We aimed to reveal the risk factors for mortality in patients showing infection caused
by Elizabethkingia spp. and find the clinical impact of their antimicrobial susceptibility patterns.
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2. Materials and Methods
2.1. Patients and Study Settings
From November 2005 to May 2016, all cases of Elizabethkingia-isolated pneumonia and bacteremia
were identified retrospectively from electronic medical records at the Severance Hospital, a major
medical center, and tertiary teaching hospital in South Korea, with a capacity of more than 2000 beds.
After excluding patients under 18 years of age, we analyzed the trend in clinicophysiologic parameters
48 h before and after sample acquisition to identify patients with confirmed Elizabethkingia infection.
Since most patients were ventilated, three systemic inflammatory response syndrome parameters: new
temperature change to <36 ◦C or >38 ◦C, a new increase in pulse rate to >90 beats per minute, and new
change in leukocyte count to <4 or >12 × 109 cells/L, were investigated. In addition, we investigated
three additional criteria: a new rise in the fraction of inspired oxygen requirement >0.1, new C-reactive
protein (CRP) > 100 mg/L, and new pulmonary infiltrates on plain chest radiography.
A total of 210 patients (186 pneumonia and 24 bacteremia patients) were enrolled. The demographic
data, medical history, simplified acute physiology score II (SAPS II), underlying diseases, Charlson
comorbidity score, clinical manifestations, vital signs, chest radiography, laboratory test results (data on
the day of microbial isolation and seven days later), microbiological data, and treatment regimen from
each patient were collected and reviewed. To assess the impact of Elizabethkingia infection, we evaluated
the 28-day mortality.
2.2. Ethical Approval and Consent to Participate
The study was approved (4-2019-1264) by the institutional review board of the Yonsei University
Health System Clinical Trial Center. The informed consent was waived because this study was a
retrospective study with review of related data through the electronic medical records.
Death occurring within 28 days after diagnosis of the Elizabethkingia infection was defined as 28-day
mortality. An episode of bacteremia was defined as the presence of one or more blood cultures that
were positive for Elizabethkingia spp., which contributed to clinical sepsis. An episode of pneumonia
was defined as the presence of sputum or bronchial alveolar lavage cultures that were positive for
Elizabethkingia spp. with infiltration in radiological imaging.
Prolonged hospitalization was defined as hospitalization for two or more weeks before the
diagnosis of bacteremia. Prior stay in an intensive care unit was defined as a stay in the intensive
care unit for more than seven days within 14 days prior to the diagnosis of bacteremia or pneumonia.
Recent surgery was defined as a surgical procedure, excluding tracheostomy, performed within one
month prior to the onset of Elizabethkingia-induced bacteremia or pneumonia. Immunosuppressive
therapy was defined as the use of cytotoxic agents or corticosteroids (more than 30 mg of prednisolone
daily or the equivalent for one week or more).
Prolonged antibiotic use was defined as the administration of intravenous antibiotics for more
than 14 days within 30 days before the diagnosis of bacteremia. Appropriate antibiotic therapy was
defined as the use of at least one intravenous antibiotic to which the microorganism was susceptible,
according to the corresponding minimum inhibitory concentration (MIC), within 72 h of diagnosis of
the infection.
2.3. Bacterial Isolates and Antimicrobial Susceptibility Testing
Species identification initially identified using the Vitek II GN card system (bioMerieux, Marcy
l’Etoile, France) but updated by two matrix-assisted laser desorption ionization time-of-flight systems,
the Bruker Biotyper (Bruker Daltonics, Bremen, Germany) and the Vitek mass spectrometry (bioMerieux,
Marcy l’Etoile, France) as described by Han et al. (2016) [33]. Strains with discrepant results were
confirmed by 16S rRNA gene sequencing using universal primers [34].
Susceptibilities of the isolates to antimicrobials were determined using epsilometer test (E-test)
strips (bioMerieux, Marcy l’Etoile, France). Sputum, bronchial alveolar lavage, and blood culture
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samples were processed using the BACTEC FX system (Becton Dickinson, Sparks, MD, USA).
All positive cultures were examined by Gram staining and were sub-cultured on blood agar plates and
eosin-methylene blue agar plates for further identification.
The following antimicrobial agents were assayed: ceftazidime, cefobactam, cefoxitin, cefotaxim,
cefepime, aztreonam, piperacilin-tazobactam, amoxicillin-clavulinate, ampicillin/sulbactam, imipenem,
meropenem, tobramycin, amikacin, gentamicin, erythromycin, minocycline, ciprofloxacin, levofloxacin,
trimethoprim–sulfamethoxazole, teicoplanin, vancomycin, tigecycline, and colistin. With no
established MIC breakpoints of Elizabethkingia spp. for moxifloxacin, the interpretive breakpoints
of non-Enterobacteriaceae for gatifloxacin were used. For the reasons mentioned above, the MIC
breakpoints for Staphylococcus spp. and Staphylococcus aureus were used to interpret the susceptibility
of rifampin and vancomycin, respectively [35].
Since 2013, moxifloxacin, rifampin, and vancomycin have been excluded from the antibiotic
susceptibility panel of Elizabethkingia spp. To compensate for the Elizabethkingia spp. susceptibility
panel, further E-tests (bioMerieux, Marcy l’Etoile, France) for those antibiotics were carried out using
122 Elizabethkingia isolates, which were stored in tryptic soy broth with 15% glycerol at −70 ◦C.
2.4. Statistical Analysis
All variables are expressed as the mean ± standard deviation unless otherwise indicated.
Continuous variables were compared with the Student t-test or the Mann–Whitney nonparametric test.
The proportions were compared with the χ2 or Fisher exact test when appropriate. Logistic regression
was used for multivariate analysis of the risk factors associated with 28-day mortality, and the results
are presented as adjusted odds ratios (OR) with 95% confidence intervals (CI). Variables were selected
for the multivariate analysis based on the level of significance of the univariate association with
28-day mortality (p < 0.05). Models were built sequentially, starting with the variable most strongly
associated with 28-day mortality and continued until no other variable reached significance or altered
the odds ratios of variables already in the model. Upon arriving at the final model, each variable
was sequentially excluded to assess its effect. Statistical analyses were performed using the Statistics
Package for Social Science (SPSS 25.0 for windows; SPSS Inc., Chicago, IL, USA). P-values less than
0.05 were considered statistically significant.
3. Results
3.1. Population Characteristics
From November 2005 to May 2016, the bacterial cultures from 492 patients yielded Elizabethkingia
spp. Among them, 43 patients aged under 18 years, 217 patients showing colonization with Elizabethkingia
spp., and 22 patients presenting with other infections (except pneumonia and bacteremia) were excluded.
Finally, 210 patients (186 pneumonia patients and 24 bacteremia patients) with Elizabethkingia infection
were enrolled during the study periods.
Table 1 summarizes the baseline characteristics of the 210 patients. The mean age of the patients
was 66.5 ± 18 years, and the 28-day mortality rate was 25.2% (53/210). The mean duration from
admission to the isolation of Elizabethkingia spp. was 55.8 ± 74.9 days. The most common underlying
disease was malignancy (n = 100), followed by cerebrovascular attack (n = 47). The majority of subjects
who contracted Elizabethkingia infection had pneumonia (n = 186).
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Table 1. Baseline characteristics of 210 patients with Elizabethkingia spp. infection.




(n = 53) p-Value
Sex (male) 129 (61.4) 98 (62.4) 31 (58.5) 0.730
Age (years) 66.5 ± 18 63.7 ± 16.5 62.5 ± 14.1 0.637
HOD (days) 55.8 ± 74.9 58.6 ± 83.2 47.6 ± 41.2 0.357
Charlson comorbidity index 3.3 ± 2.1 3.2 ± 2.2 3.5 ± 2.1 0.419
SAPS II 47.7 ± 21.3 43.5 ± 20.2 59.9 ± 19.8 <0.001
Underlying disease, yes
MI 25 (11.9) 17 (10.8) 8 (15.1) 0.409
CHF 30 (14.3) 22 (14.0) 8 (15.1) 0.846
PAOD 9(4.3) 7 (4.5) 2 (3.8) 0.831
Cerebrovascular attack 47 (22.4) 39 (24.8) 8 (15.1) 0.141
Dementia 10 (4.8) 8 (5.1) 2 (3.8) 0.696
Chronic pulmonary disease 43 (20.5) 34 (21.7) 9 (17.0) 0.466
Connective tissue disease 7 (3.3) 5 (3.2) 2 (3.8) 0.836
Liver disease 21 (10.0) 14 (8.9) 7 (13.2) 0.427
Diabetes mellitus 41 (19.5) 32 (20.4) 9 (17.0) 0.589
Hemiplegia 14 (6.7) 13 (8.3) 1 (1.9) 0.198
CKD 41 (19.5) 30 (19.1) 11 (20.8) 0.794
ESRD 28 (13.3) 21 (13.5) 7(13.2) 0.963
Malignancy 100 (47.6) 73 (46.5) 27 (50.9) 0.634
Transplantation
SOT 17 (8.1) 12 (7.6) 5 (9.4) 0.771
PBSCT 8 (3.8) 6 (3.8) 2 (3.8) >0.999
Polymicrobial infection 97 (46.2) 80 (51.0) 17 (32.1) 0.017
Source of infection 0.304
Pneumonia 186 (88.6) 137 (87.3) 49 (92.5)
Primary bacteremia 24 (11.4) 20 (12.7) 4 (7.5)
HOD, hospital days of acquisition; SAPS II, simplified acute physiology score II; MI, myocardial infarction; CHF,
congestive heart failure; PAOD, peripheral artery occlusive disease; CKD, chronic kidney disease; ESRD, end stage
renal disease; SOT, Solid organ transplantation; PBSCT, Peripheral blood stem cell transplantation. Continuous
variables are shown as the mean ± standard deviation (SD) and categorical variables, as numbers (percentage).
The survivors had a lower SAPS II score (43.5 ± 20.2 vs. 59.9 ± 19.8, p < 0.001) and a higher
incidence of concomitant pathogens (80 (51.0%) vs. 17 (32.1%), p = 0.017) than the non-survivors
(Table 1). Charlson comorbidity index, prolonged hospitalization, and underlying disease were not
statistically different between the two groups.
Table 2 describes the clinical conditions and laboratory data among patients with Elizabethkingia
infection. In comparison with survivors, the non-survivors presented a higher percentage with regard to
the following aspects: previous intensive care unit (ICU) admission (40 (75.5%) vs. 89 (56.7%), p = 0.015),
central venous catheter use (48 (90.6%) vs. 121 (77.1%), p = 0.032), and immunocompromised status
(24 (45.3%) vs. 42 (26.8%), p = 0.012). Non-survivors who reported a high rate of thrombocytopenia
(34 (64.2%) vs. 47 (29.9%), p < 0.001) and CRP/albumin ratio (50.4 ± 37.2 vs. 22.6 ± 26.9, p < 0.001)
on the day of isolation also reported significantly higher rates of thrombocytopenia (23 (63.9%) vs.
38 (26.0%), p < 0.001) and CRP/albumin ratio (45.7 ± 30.1 vs. 18.2 ± 18.9, p < 0.001) seven days later.
In contrast to these parameters, hypoalbuminemia was remarkable on the days of isolation (34 (64.2%)
vs. 64 (41.0%), p = 0.004), but was not significant seven days later (20 (57.1%) vs. 61 (42.1%), p = 0.108).
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Table 2. Comparisons of clinical conditions and laboratory data between survivors and non-survivors.




(n = 53) p-Value
Predisposing conditions, yes
Prior stay in ICU 129 (61.4) 89 (56.7) 40 (75.5) 0.015
Recent surgery 44 (21.0) 31 (19.7) 13 (24.5) 0.459
Ventilator use 149 (71.0) 107 (68.2) 42 (79.2) 0.124
Multiple injuries 4 (1.9) 4 (2.5) 0(0.0) 0.574
Immunocompromised status, yes 66 (31.4) 42 (26.8) 24 (45.3) 0.012
Invasive device use, yes
Central venous catheter 169 (80.5) 121 (77.1) 48 (90.6) 0.032
Foley catheter 178 (85.2) 130 (83.3) 48 (90.6) 0.201
Endotracheal tube 163 (77.6) 121 (77.1) 42 (79.2) 0.743
Port-A catheter 6 (2.9) 4 (2.5) 2 (3.8) 0.644
Cerebrospinal shunt 5 (2.4) 4 (2.5) 1 (1.9) >0.999
Pleural catheter 36 (17.1) 24 (15.3) 12 (22.6) 0.219
Pancreaticobiliary catheter 8 (3.8) 5 (3.2) 3 (5.7) 0.419
Laboratory test on Day 0
Leukocytosis (>10,000 mm/µL) 135 (64.3) 102(65.0) 33 (62.3) 0.722
RDW (%) 16.4 ± 2.5 15.7 ± 2.7 16.8 ± 4.0 0.221
Delta-neutrophil (%) 6.0 ± 20.1 1.7 ± 3.1 3.0 ± 6.0 0.727
Thrombocytopenia, yes (/µL) 81 (38.6) 47 (29.9) 34 (64.2) <0.001
Severe thrombocytopenia, yes (/µL) 26 (12.4) 13 (8.3) 13 (24.5) 0.002
Hypoalbuminemia, yes (g/dL) 98 (46.9) 64 (41.0) 34 (64.2) 0.004
CRP/albumin ratio 26.6 ± 29.3 22.6 ± 26.9 50.4 ± 37.2 <0.001
Renal insufficiency, yes (%) 60 (28.6) 47 (29.9) 13 (24.5) 0.451
Laboratory test on Day 7
Leukocytosis (>10,000/µL) 123 (67.6) 101 (69.2) 22 (61.1) 0.354
RDW (%) 16.7 ± 2.3 16.2 ± 2.4 16.6 ± 2.3 0.210
Delta-neutrophil (%) 3.7 ± 7.7 5.1 ± 19.7 6.3 ± 13.2 0.072
Thrombocytopenia, yes (/µL) 61 (33.5) 38 (26.0) 23 (63.9) <0.001
Severe thrombocytopenia, yes (/µL) 21 (11.5) 11 (7.5) 10 (27.8) 0.001
Hypoalbuminemia, yes (g/dL) 81(45.0) 61 (42.1) 20 (57.1) 0.108
CRP/albumin ratio 24.3 ± 25.0 18.2 ± 18.9 45.7 ± 30.1 <0.001
Renal insufficiency, yes (%) 52 (28.6) 43 (29.5) 9 (25.0) 0.596
ICU, Intensive Care Unit; RDW, Red Cell Distribution Width; CRP, C-reactive protein of acquisition. Renal
insufficiency was defined as a calculated glomerular filtration rate (GFR) of less than 60 mL per minute/1.73 m2.
Thrombocytopenia and severe thrombocytopenia were defined as a platelet count of less than 100,000 and
50,000 per µL, respectively. Hypoalbuminemia was defined as a low blood level of albumin of less than 2.8 g per dL.
Continuous variables are shown as the mean ± standard deviation (SD) and categorical variables, as numbers
(percentage).
3.2. Antibiogram Patterns and Therapeutic Regimens
The list of isolated Elizabethkingia species, their susceptibility to antibiotics, and the MICs of the
antimicrobial agents for these species are shown in Table 3. E. meningoseptica was the most common
pathogenic member among Elizabethkingia species (n = 132), and its contribution to mortality was similar
to that of the other species. The results of E-tests for moxifloxacin, rifampin, and vancomycin from 122
preserved Elizabethkingia isolates were added to the previously examined data of the susceptibilities
of Elizabethkingia spp. For the non-survivor group, the antibiotic susceptibility rate was found to be
low for rifampin and vancomycin, and high for moxifloxacin, but no statistical significance was seen.
In addition, the MIC value of rifampin in the non-survivor group was significantly higher than that in
the survivor group (11.9 ± 15.6 vs. 6.0 ± 11.7, p = 0.031). The proportion of isolated Elizabethkingia
species and their susceptibility rate to antimicrobial agents are shown in Figure 1. Regardless of the
type of Elizabethkingia species, both moxifloxacin and vancomycin were active against these pathogens.
However, rifampin, which was related to the mortality associated with Elizabethkingia infections,
showed various susceptibilities and was the most active against E. miricola.







Figure 1. The proportion of isolated Elizabethkingia species and in vitro antibiotic susceptibility rate of
three Elizabethkingia species. The proportions of three Elizabethkingia species are presented in a pie chart,
and the percentage of each species is shown in parentheses. The susceptibilities of each Elizabethkingia
species to three antibiotics (moxifloxacin, rifampin, and vancomycin) are also presented in bar charts.
(A), E. anopheles, (B), E. miricola, and (C), E. meningoseptica, respectively.
J. Clin. Med. 2020, 9, 1431 8 of 13
The treatment duration and antimicrobial treatment regimens in the study population are described
in Table 4. More than 80% of the patients had a history of prolonged antibiotics usage at the time of
the isolation of Elizabethkingia spp. A majority of the therapeutic procedures involved a combination
of antibiotics (n = 187). The antimicrobial regimen including glycopeptide was the most common
(n = 127). No differences according to the antimicrobial regimen were observed between the survivor
and non-survivor groups, except in case of the anti-pseudomonal penicillin plus glycopeptide regimen
(20 (12.7%) vs. 2 (3.8%), p = 0.045).
Table 3. Antibiogram patterns of Elizabethkingia spp. infection.




(n = 53) p-Value
Elizabethkingia (%) 0.513
E. meningoseptica 132 (62.9) 94 (59.9) 38 (71.7) 0.123
E. anophelis 38 (18.1) 30 (19.1) 8 (15.1) 0.512
E. miricola 15 (7.1) 12 (7.6) 3 (5.7) 0.765
Species not identified 25 (11.9) 21 (13.4) 4 (7.5) 0.257
Susceptibility, yes (%)
Minocycline 186 (89.4) 138 (89.0) 48 (90.6) 0.805
Cotrimoxazole 150 (72.1) 116 (77.3) 34 (64.2) 0.157
Anti-pseudomonal penicillins 18 (8.7) 13 (8.4) 5 (9.4) 0.782
Moxifloxacin 103 (84.4) 76 (82.6) 27 (90.0) 0.400
Rifampin 92 (76.0) 73 (80.2) 19 (63.3) 0.060
Vancomycin 134 (96.4) 102 (95.3) 32 (23.9) 0.589
MIC (ug/mL)
Moxifloxacin (range: 0.012 to >32) 2.0 ± 5.7 2.1 ± 5.7 1.5 ± 5.9 0.636
Rifampin (range: 0.008 to >32) 7.5 ± 13.0 6.0 ± 11.7 11.9 ± 15.6 0.031
Vancomycin (range: 0.050 to >256) 12.2 ± 39.4 14.6 ± 45.1 4.6 ± 3.1 0.230
MIC, minimal inhibitory concentration. Continuous variables are shown as the mean ± SD (standard deviation) and
categorical variables, as numbers (percentage).
Table 4. Antimicrobial treatment regimen for 210 patients with Elizabethkingia spp. infection.




(n = 53) p-Value
Prolonged antibiotics use (%) 177 (84.3) 129 (82.2) 48 (90.6) 0.146
Appropriate antibiotic therapy (%) 92 (44.2) 70 (45.2) 22 (41.5) 0.644
Antibiotics therapy 0.803
Monotherapy 23 (11.0) 18 (11.5) 5 (9.4)
Combination therapy 187 (89.0) 139 (88.5) 48 (90.6)
Antibiotics regimen
Monotherapy
Glycopeptide 127 (60.5) 97 (61.8) 30 (56.6) 0.505
Carbapenem 124 (59.0) 90 (57.3) 34 (64.2) 0.382
Fluroquinolone 69 (32.9) 51 (32.5) 18 (34.0) 0.843
Cephalosporin 54 (25.7) 39 (24.8) 15 (28.3) 0.618
Colistin 54 (25.7) 36 (22.9) 18 (34.0) 0.112
Anti-pseudomonal penicillin 37 (17.6) 30 (19.1) 7 (13.2) 0.330
Cotrimoxazole 34 (16.2) 22 (14.0) 12 (22.6) 0.140
Aminoglycoside 16 (7.6) 10 (6.4) 6 (11.3) 0.242
Combination therapy
Carbapenem+glycopeptide 94 (44.8) 72 (45.9) 22 (41.5) 0.582
Carbapenem+colistin 39 (18.6) 26 (16.6) 13 (24.5) 0.197
Fluroquinolone+glycopeptide 39 (18.6) 28 (17.8) 11 (20.8) 0.636
Anti-pseudomonal penicillin+glycopeptide 22 (10.5) 20 (12.7) 2 (3.8) 0.045
Anti-pseudomonal
penicillin+fluroquinolone 10 (4.8) 8 (5.1) 2 (3.8) >0.999
Carbapenem+aminoglycoside 9 (4.3) 6 (3.8) 3 (5.7) 0.695
Categorical variables are shown as numbers (percentage).
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3.3. Risk Factors for 28-day Mortality
In the multivariate logistic regression analysis, the MIC of rifampin was associated with 28-day
mortality (OR: 1.045; 95% CI: 1.006–1.085; p = 0.023). As the SAPS II increased, the mortality also
increased (OR: 1.053; 95% CI: 1.022–1.084; p = 0.001). The initial CRP/albumin ratio also had an
association with 28-day mortality (OR: 1.030; 95% CI: 1.009–1.051; p = 0.004).
4. Discussion
Elizabethkingia spp. is an emerging nosocomial pathogen. It is known that E. meningoseptica
colonizes in human oropharynx [36], respiratory secretions [4], aerosol tubes [36], endotracheal
tubes [8,36], and the respiratory tract in ventilated adult patients [37–39]. It has been found that
Elizabethkingia spp. is not only a human colonizer, but also an opportunistic pathogen causing
in-hospital outbreaks [18,39,40] resulting in high mortality [3,38].
A possible explanation for the high mortality rate may be its potential to form biofilms. The biofilms
produced by biofilm-forming pathogens, like Elizabethkingia spp., might decrease the immune response
and increase resistance against antibiotics, resulting in a high mortality rate [2]. Previous studies
have presented that the cumulative mortality rate of E. meningoseptica infections was considerable in
non-neonates (25%; [19], and 30%; [41]). The results of our study demonstrate that the 28-day mortality
rate of E. meningoseptica infections was 25.2%, consistent with previously reported mortality.
In this study, we investigated the risk factors for mortality in patients with Elizabethkingia spp.
infection. According to the multivariate logistic regression analysis, higher MIC of rifampin, increased
SAPS II, and elevated CRP/albumin ratio on the day of bacteremia were significantly related to
mortality. Previous studies have demonstrated that severe underlying diseases [42], prolonged
hospitalization, treatment with invasive procedures, prior use of broad-spectrum antimicrobials,
concomitant infections [35], and ICU stay [14] impacted survival rates. Moreover, Lin et al. reported
that the usage of intravenous catheters was a predictor of fatal outcomes [31]. Since an increased SAPS
II and elevated CRP/albumin ratio usually reflect disease severity, our results are in line with those
of previous studies. The early identification of these clinical factors in patients with Elizabethkingia
infection could be essential to improve prognosis.
Several studies have reported that a lack of treatment with effective antibiotics was an independent
predictor of mortality [14,31,42]. Contrary to our expectations, this study did not find a significant
difference between survivors and non-survivors with regard to effective antibiotic use. A possible
explanation for this might be that other co-pathogens could make it difficult to differentiate the impact
of Elizabethkingia spp. and may reflect the influence of other co-pathogens on the mortality rates;
about half of the patients in the study showed infection with at least two pathogens. Interestingly, we
found that the survivors had a higher incidence of co-pathogens than the non-survivors. It might be
suggested that Elizabethkingia may not act as a true pathogen when they mixed with other pathogens.
The most important clinically relevant finding in our study is that the elevated MIC value of
rifampin was an independent risk factor associated with the mortality of Elizabethkingia infections.
As the MIC value of rifampin increased, the mortality rate associated with Elizabethkingia infections
increased. It might be explained by mutations in RNA polymerase. RNA polymerase mutations not
only induce rifampin resistance but also cause other alterations, especially virulence-related factors. For
instance, Staphylococcus aureus, one of the biofilm-forming bacteria like Elizabethkingia, which gained
RNA polymerase mutations showing a high level of rifampin MIC values, presented the elevated
capacity for biofilm formation [43].
Owing to its marked intrinsic resistance, particularly toβ-lactam antibiotics [18,38,42,44,45], there has
been no consensus on the drug of choice for E. meningoseptica infection. One interesting finding was that
paradoxically, E. meningoseptica presented sensitivity to antibiotics that have effects against Gram-positive
bacteria, such as fluoroquinolones, rifampin, TMP-SMX, and vancomycin [9,35]. It is interesting to note
that this research found that Elizabethkingia spp. presented high susceptibility to rifampin, moxifloxacin,
and vancomycin. These results are consistent with those observed in earlier studies.
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A recent study showed that three Elizabethkingia spp. (E. meningoseptica, 100%; E. miricola,
94.4%; E. anophelis, 94.4%) have high susceptibility to rifampin [46]. Due to its higher susceptibility
and relevance to mortality, rifampin could be a promising candidate for a treatment regimen
against Elizabethkingia spp. infections. Previous studies also suggest that rifampin [40],
moxifloxacin [9,14,29,47], minocycline [38,42,48], TMP-SMX alone [49] or in combination with
ciprofloxacin [50], and anti-pseudomonal penicillins plus amikacin [51] could be considered as potential
treatment strategies for Elizabethkingia spp. infections. Since 2013, the antibiotics susceptibility panel
for Elizabethkingia spp. in our hospital did not include rifampin; hence, clinical data of rifampin usage
for Elizabethkingia seldom exists. Further research investigating the appropriate antibiotic regimens,
including those of rifampin, is essential to reduce the risk of mortality of Elizabethkingia infection.
An E-test for moxifloxacin demonstrated that it remained an active agent against all three
Elizabethkingia spp. However, there were no significant differences in the mortality between groups
that used moxifloxacin and those that did not. It might result from the bacteria’s several mechanisms
facilitating resistance include acquisition of efflux pumps or protection enzyme encoding plasmids
that inactivate the fluoroquinolone [52].
Pereira et al. (2013) recommended vancomycin as a drug of choice for neonatal meningitis caused
by E. meningoseptica [35]. Chang et al. (2019) reported the low resistance of Elizabethkingia spp. against
vancomycin (E. meningoseptica, 0%; E. miricola, 21.4%; E. anophelis, 4.2%) [46]. In our study, however, no
significant correlation was found between vancomycin usage and mortality following Elizabethkingia
infection. This inconsistency may be due to the discrepancy of the target of vancomycin usage. Usually,
vancomycin is used against Gram-positive bacteria. Elizabethkingia species are Gram-negative, hence,
the purpose of vancomycin usage was perhaps, not to cure Elizabethkingia infection, but instead control
the growth of other Gram-positive bacteria.
It is interesting to note that in univariate analysis, survivors of this study showed efficacy
not for anti-pseudomonal penicillin or vancomycin alone, but anti-pseudomonal penicillin plus
glycopeptide regimen. These may result reflect those of Di Pentima et al. (1998) who also found that
in vitro vancomycin synergy against Elizabethkingia meningoseptica (originally named Flavobacterium
meningoseptica) [53,54]. Considering its resistant mechanism, glycopeptides that disrupt the bacterial
membrane could make it easy for beta-lactams to penetrate the bacteria resulting in favorable
outcomes [52]. It can thus be suggested that in severe Elizabethkingia-infected patients, vancomycin
accompanied by rifampin or anti-pseudomonal penicillin can be promising candidates unless their
antibiotics susceptibility test presented resistance. There are several limitations to our study. First, our
study is retrospective. The history of antibiotics usage was dependent on electronic medical records
and no intervention was performed with regard to the choice of antibiotics. Secondly, our study
population was quite small to determine the risk factors affecting mortality. Finally, we summarized
three Elizabethkingia spp. to analyze the risk factors for mortality. The mortality rates for infections
caused by each species could be different. However, upon checking for differences in the mortality
based on the type of species, we found that the mortalities of the infections caused by the three species
were similar. Despite these limitations, our study revealed that rifampin is the most active agent
against the Elizabethkingia spp. Further randomized controlled trials with more subjects need to be
undertaken to support our results.
5. Conclusions
We conducted this study to identify the risk factors for the mortality associated with Elizabethkingia
infections and to find the clinical impacts of the antimicrobial susceptibility patterns of Elizabethkingia
spp., which are emerging nosocomial pathogens. Our results suggest that the MIC values of rifampin,
SAPS II score, and initial CRP/albumin ratio were significantly related to the 28-day mortality associated
with infections caused by Elizabethkingia spp.
Prediction of patients’ clinical courses using initial CRP/albumin ratio and SAPS II is a priority to
reduce the mortality caused by Elizabethkingia infections. Rifampin is a promising candidate as the
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drug of choice for Elizabethkingia infection. Therefore, to reduce the mortality, the use of antibiotics in
Elizabethkingia-infected patients based on these predictors should be carefully considered.
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